ストックスクリーナーアプリを入手
14.62
10.17%
1.35
アフターアワーズ：
14.40
-0.22
-1.50%
Crescent Biopharma Inc (CBIO) 最新ニュース
Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Avidity Biosciences Shares Are Under the Spotlight - TipRanks
Massive $200M Biotech Deal: Crescent Biopharma Secures Funding for Cancer Breakthrough Pipeline - Stock Titan
Crisis as catalyst: From Chernobyl evacuation to biotech innovation - BioXconomy
Gyre Therapeutics announces first doing in Phase 1 trial of F230 - TipRanks
How To Trade (GYRE) - news.stocktradersdaily.com
Is Costco's BNPL Push a Catalyst for Big-Ticket E-Commerce? - The Globe and Mail
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Hemophilia with Inhibitor Market Statistics Expected - openPR.com
A.I. Drone Operations Flourishing as Global Quantum Computing Market Expected to Reach $5.3 Billion By 2029 - The Globe and Mail
Forge Resources Announces Closing of Further Interest to 80% in Fully Permitted Coal Project, Colombia - The Globe and Mail
Quantum Computing Technology Evolving as Larger Scale of Applications & Uses Skyrockets - The Globe and Mail
AI Analyst Flags Key Risks and Upside for Nvidia Ahead of Earnings - The Globe and Mail
Prediction: SoundHound AI Stock Will Beat the Market. Here's Why. - The Globe and Mail
Zacks Investment Ideas feature highlights: CyberArk, Lam Research and monday.com - The Globe and Mail
(GYRE) Long Term Investment Analysis - news.stocktradersdaily.com
SBAC Stock Rises 12% Year to Date: Will the Trend Continue? - The Globe and Mail
GYRE Trading Resumes After Temporary Halt | GYRE Stock News - GuruFocus
Trading Halted for Catalyst Biosciences (GYRE) Due to Volatility - GuruFocus
Trading Halted for Catalyst Biosciences (GYRE) Due to Volatility | GYRE Stock News - GuruFocus
Factor Investing in Focus: What ETFs Say About Market Direction - The Globe and Mail
Is Navitas Semiconductor Stock a buy After Nvidia Enters the Room? - The Globe and Mail
Where Will Rigetti Computing Be in 3 Years? - The Globe and Mail
Here's How I'd Invest $10,000 Today - The Globe and Mail
How the (GYRE) price action is used to our Advantage - news.stocktradersdaily.com
Barclays Reaffirms Their Hold Rating on Floor & Decor Holdings (FND) - The Globe and Mail
Why JD.com Stock Slumped on Thursday - The Globe and Mail
Will Crimson Data Add Shine To Catalyst Biosciences? - RTTNews
Where are the Opportunities in (GYRE) - news.stocktradersdaily.com
IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events – Company Announcement - Financial Times
Press Release Distribution & PR Platform - ACCESS Newswire
Corteva Invests in Desert Bacteria Startup That Boosted Crop Yields 15% Across 800,000 Acres - Stock Titan
Puna Bio receives investment from Corteva Catalyst - Yahoo Finance
Carnival Is Down 27% in 2025. Is This a Once-in-a-Lifetime Buying Opportunity Before the Stock Goes Parabolic? - The Globe and Mail
Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025 (NASDAQ:DRUG) - Seeking Alpha
AbCellera: Attractively Priced But A Catalyst Is Needed - Seeking Alpha
Spotting Winners: Teleflex (NYSE:TFX) And Surgical Equipment & ConsumablesSpecialty Stocks In Q4 - The Globe and Mail
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Geode Capital Management LLC - Defense World
Wellington Management Group LLP Sells 8,034 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily
(GYRE) Proactive Strategies - news.stocktradersdaily.com
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by Sei Investments Co. - Defense World
Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts - Seeking Alpha
Gyre Therapeutics announces NMPA approval for trial on pirfenidone - TipRanks
Business - isStories
Gyre Therapeutics announces publication of protocol for Phase 3 trial on F351 - TipRanks
Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win - Investor's Business Daily
GyreIntriguing Upcoming Data Catalyst, But I'm Still On Sidelines (NASDAQ:GYRE) - Seeking Alpha
3 Reasons to Avoid LUMN and 1 Stock to Buy Instead - The Globe and Mail
Hemophilia B Pipeline 2024: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Novo Nordisk, Sanofi, Pfizer, Belief BioMed, Centessa Pharma - Barchart
Avidity Biosciences Shares Tumble Despite Trial Success - TipRanks
How to Take Advantage of moves in (GYRE) - Stock Traders Daily
Avidity Biosciences Stock Climbs Amid Promising Prospects - TipRanks
Annexon: Despite Major Catalysts, Stock Is Trading Almost At Cash (NASDAQ:ANNX) - Seeking Alpha
Should Artificial Intelligence (AI) Stock Investors Buy ASML Stock? - The Globe and Mail
Elon Musk Blamed for TSLA Stock Siege as Wall St. Expects 53% Rebound - The Globe and Mail
(GYRE) Investment Analysis - news.stocktradersdaily.com
Vir Biotechnology: Catalysts Ahead In Hepatitis And Oncology (NASDAQ:VIR) - Seeking Alpha
Global Blood Bank Market to Register Immense Growth at a CAGR of ~7% by 2032 | DelveInsight - GlobeNewswire
PainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors - ACCESS Newswire
Harmony Biosciences Highlights 2025 Catalysts in Sleep/Wake Franchise - Sleep Review
Arcus Biosciences' SWOT analysis: promising pipeline drives stock outlook - Investing.com
Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In? - Yahoo Finance
Allspring Global Investments Holdings LLC Has $8.71 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Solid Bio stock rises on data for Duchenne drug (SLDB:NASDAQ) - Seeking Alpha
Key Trend Revolutionizing the Acquired Hemophilia Treatment Market in 2025: Expansion of Routine Prophylaxi... - WhaTech
2.13%
1.01%
大文字化:
|
ボリューム (24 時間):